TAM
SLDB icon

Tiverton Asset Management’s Solid Biosciences SLDB Stock Holding History

Tiverton Asset Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-348
Closed -$140K – 663
2018
Q4 		$140K Buy
+348
New +$164K 0.01% 339

Other funds holding SLDB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Tiverton Asset Management's SLDB Position: Q1 2019 in Review

Tiverton Asset Management sold out of Solid Biosciences (SLDB) in Q1 2019, closing a stake of 348 shares — an estimated $140K sold.

Tiverton Asset Management first reported a position in SLDB in Q4 2018 and held it in 1 quarter. The position peaked at $140K in Q4 2018. 74 funds tracked by Wall St. Rank hold SLDB as of Q1 2019.

  • Tiverton Asset Management reported no remaining Solid Biosciences position as of Q1 2019 after selling out during the quarter.
  • Tiverton Asset Management sold 348 Solid Biosciences shares in Q1 2019, an estimated $140K.
  • Tiverton Asset Management first reported a position in Solid Biosciences in Q4 2018 and held it in 1 quarter.
  • Tiverton Asset Management's Solid Biosciences position peaked at $140K in Q4 2018.
  • 74 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2019.

Based on Tiverton Asset Management's 13F filing for Q1 2019, filed 13 May 2019.